Nishikant Damle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nishikant Damle has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Chandrasekhar Bal
Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, 110029, India
8 shared publicationsPraveen Kumar
Department of Nuclear Medicine, AIIMS, New Delhi, India
4 shared publicationsManish Patnecha
Department of Nuclear Medicine, All India Institute of Medical Sciences, Room no. 59 A, A.I.I.M.S, New Delhi, 110029 India
2 shared publicationsSagar Maharjan
Department of Nuclear Medicine, AIIMS, New Delhi, India
2 shared publicationsSandeep Mathur
Department of Pathology, AIIMS, New Delhi, India
2 shared publicationsAnil K Pandey
1 shared publication
Latest Publications
- 2 January 2018
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (4) , 667-668
Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers
- 2 January 2018
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 45 (4) , 667-668
Anaplastic thyroid carcinoma on 68 Ga-PSMA PET/CT: opening new frontiers
- 7 August 2014
- Vol. 17 (2) , 106-10
Production of the PET bone agent (18)F-fluoride ion, simultaneously with (18)F-FDG by a single run of the medical cyclotron with minimal radiation exposure- a novel technique.
Our aim was to establish an easy and convenient procedure for the preparation of fluorine-18-sodium fluoride ((18)F-NaF) for bone positron emission tomography (PET) during routine (18)F-FDG production using the Explora FDG4 radiochemistry module (EFRM) by single run of Cyclotron with negligible radiation exposure. We compared three techniques for (18)F-NaF production during routine PET radiochemistry at our setup. In one method we used synthesis module and in other two methods we did not. In the first and third method, F-18 was directly extracted from the V-vial and in the second method, (18)F-NaF was extracted by post processing from the EFRM. In the first method, F-18 was extracted directly from V-vial manually by opening the V-vial cap. In the second method, Explora FDG-4 Module was used. First, F-18 was transferred from the V-vial. Then, after post processing in EFRM, pure F-18 was obtained in the product vial. In the third method, pure F-18 was obtained in the product vial with the help of a mechanical robotic arm. The above were followed by routine quality control of (18)F-NaF produced by each method. Results of quality control of the (18)F-NaF obtained by all three methods satisfied all parameters prescribed by the United States Pharmacopeia (USP) and the British Pharmacopeia (BP) including biological, physical and chemical specifications. The radiochemical purity was 98.5±1.5% with Rf 0.006. The level of Kryptofix-222 (K222) in (18)F-NaF was within the prescribed limit. Mean pH of (18)F-NaF was 6.0±1.5. The exposure rate around the hot cell was negligible. In conclusion, from the results it was obvious that by our method number three (18)F-NaF was directly obtained from the V-vial using mechanical robotic arms. This method was the most appropriate with minimized radiation exposure to the handling Radiochemist and was also saving time as compared to the other two methods.
- 7 August 2014
- Vol. 17 (2) , 106-10
Production of the PET bone agent (18)F-fluoride ion, simultaneously with (18)F-FDG by a single run of the medical cyclotron with minimal radiation exposure- a novel technique.
Our aim was to establish an easy and convenient procedure for the preparation of fluorine-18-sodium fluoride ((18)F-NaF) for bone positron emission tomography (PET) during routine (18)F-FDG production using the Explora FDG4 radiochemistry module (EFRM) by single run of Cyclotron with negligible radiation exposure. We compared three techniques for (18)F-NaF production during routine PET radiochemistry at our setup. In one method we used synthesis module and in other two methods we did not. In the first and third method, F-18 was directly extracted from the V-vial and in the second method, (18)F-NaF was extracted by post processing from the EFRM. In the first method, F-18 was extracted directly from V-vial manually by opening the V-vial cap. In the second method, Explora FDG-4 Module was used. First, F-18 was transferred from the V-vial. Then, after post processing in EFRM, pure F-18 was obtained in the product vial. In the third method, pure F-18 was obtained in the product vial with the help of a mechanical robotic arm. The above were followed by routine quality control of (18)F-NaF produced by each method. Results of quality control of the (18)F-NaF obtained by all three methods satisfied all parameters prescribed by the United States Pharmacopeia (USP) and the British Pharmacopeia (BP) including biological, physical and chemical specifications. The radiochemical purity was 98.5±1.5% with Rf 0.006. The level of Kryptofix-222 (K222) in (18)F-NaF was within the prescribed limit. Mean pH of (18)F-NaF was 6.0±1.5. The exposure rate around the hot cell was negligible. In conclusion, from the results it was obvious that by our method number three (18)F-NaF was directly obtained from the V-vial using mechanical robotic arms. This method was the most appropriate with minimized radiation exposure to the handling Radiochemist and was also saving time as compared to the other two methods.
- Open Access
- 1 January 2013
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 17 (2) , 353-4
Inguinal node metastasis from follicular thyroid cancer
Indian J Endocr Metab, Official publication of Endocrine Society of India,India
- 1 January 2013
- Published by Medknow in Indian Journal of Endocrinology and Metabolism
- Vol. 17 (2) , 353-4
Open AccessInguinal node metastasis from follicular thyroid cancer
Indian J Endocr Metab, Official publication of Endocrine Society of India,India
- 1 October 2012
- Published by Springer Nature in Hormones
- Vol. 11 (4) , 451-457
The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter
Radioactive iodine uptake (RAIU) is a test used to differentiate hyperthyroidism from thyroiditis and to calculate the radioiodine dose for treatment of Graves' disease. We aimed to evaluate the predictive role of 24h RAIU with respect to the outcome of radioiodine therapy in patients with diffuse toxic goiter (DTG). Case records of patients with DTG treated with radioactive iodine were reviewed retrospectively. Patients were divided into two groups based on 24h RAIU (normal range: 15% - 35% at 24 h): the first group included patients with 24h RAIU values equal to or less than 50%, while the second group included patients with 24h RAIU values of over 50%. Gland size, duration of disease, treatment with antithyroid drugs (ATD) and its duration were the other factors considered. Success of the first dose of 131I was defined as a euthyroid or hypothyroid status at 12 months post-therapy without the need for additional radioiodine or ATD therapy. Data were analyzed with 95% power and 1% type I error (α=0.01). Six hundred thirty-three (633) consecutive patients with DTG were given a fixed-dose (5mCi) of radioiodine between January 1987 and December 2006. One hundred seventy-five patients (175) had an RAIU ≤50% and 458 patients had an RAIU >50%. First-dose success rate in the former group was 81.7% and in the second group 68.6% (p=0.001). The overall first-dose success was 72%. Multivariate analysis confirmed the significant role of 24h RAIU data to predict a successful outcome. A 24h RAIU value of ≤50% appears to be associated with a significantly better outcome compared to that of a 24h RAIU value of >50% in patients with DTG given as treatment a fixed dose of 185 MBq radioiodine.
- 1 October 2012
- Published by Springer Nature in Hormones
- Vol. 11 (4) , 451-457
The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter
Radioactive iodine uptake (RAIU) is a test used to differentiate hyperthyroidism from thyroiditis and to calculate the radioiodine dose for treatment of Graves' disease. We aimed to evaluate the predictive role of 24h RAIU with respect to the outcome of radioiodine therapy in patients with diffuse toxic goiter (DTG). Case records of patients with DTG treated with radioactive iodine were reviewed retrospectively. Patients were divided into two groups based on 24h RAIU (normal range: 15% - 35% at 24 h): the first group included patients with 24h RAIU values equal to or less than 50%, while the second group included patients with 24h RAIU values of over 50%. Gland size, duration of disease, treatment with antithyroid drugs (ATD) and its duration were the other factors considered. Success of the first dose of 131I was defined as a euthyroid or hypothyroid status at 12 months post-therapy without the need for additional radioiodine or ATD therapy. Data were analyzed with 95% power and 1% type I error (α=0.01). Six hundred thirty-three (633) consecutive patients with DTG were given a fixed-dose (5mCi) of radioiodine between January 1987 and December 2006. One hundred seventy-five patients (175) had an RAIU ≤50% and 458 patients had an RAIU >50%. First-dose success rate in the former group was 81.7% and in the second group 68.6% (p=0.001). The overall first-dose success was 72%. Multivariate analysis confirmed the significant role of 24h RAIU data to predict a successful outcome. A 24h RAIU value of ≤50% appears to be associated with a significantly better outcome compared to that of a 24h RAIU value of >50% in patients with DTG given as treatment a fixed dose of 185 MBq radioiodine.
- Open Access
- 1 September 2011
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 2 (3) , 193-196
Radioiodine Avid Axillary Lymph Node Metastasis in Papillary Thyroid Cancer: Report of a Case
- 1 September 2011
- Published by Springer Nature in Indian Journal of Surgical Oncology
- Vol. 2 (3) , 193-196
Open AccessRadioiodine Avid Axillary Lymph Node Metastasis in Papillary Thyroid Cancer: Report of a Case
- 12 May 2011
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 45 (3) , 212-216
SPECT/CT in the Diagnosis of Skull Base Osteomyelitis
Skull base osteomyelitis is a potentially fatal disease. We demonstrate here the utility of SPECT/CT in diagnosing this entity, which was not obvious on a planar bone scan. A 99mTc MDP bone scan with SPECT/CT was carried out on a patient with clinically suspected skull base osteomyelitis. Findings were correlated with contrast-enhanced CT (CECT) and MRI. Planar images were equivocal, but SPECT/CT showed intense uptake in the body of sphenoid and petrous temporal bone as well as the atlas corresponding to irregular bone destruction on CT and MRI. These findings indicate that SPECT/CT may have an additional role beyond planar imaging in the detection of skull base osteomyelitis.
- 12 May 2011
- Published by Springer Nature in Nuclear Medicine and Molecular Imaging
- Vol. 45 (3) , 212-216
SPECT/CT in the Diagnosis of Skull Base Osteomyelitis
Skull base osteomyelitis is a potentially fatal disease. We demonstrate here the utility of SPECT/CT in diagnosing this entity, which was not obvious on a planar bone scan. A 99mTc MDP bone scan with SPECT/CT was carried out on a patient with clinically suspected skull base osteomyelitis. Findings were correlated with contrast-enhanced CT (CECT) and MRI. Planar images were equivocal, but SPECT/CT showed intense uptake in the body of sphenoid and petrous temporal bone as well as the atlas corresponding to irregular bone destruction on CT and MRI. These findings indicate that SPECT/CT may have an additional role beyond planar imaging in the detection of skull base osteomyelitis.
- Open Access
- 1 January 2011
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 26 (4) , 196-8
Solid variant of papillary carcinoma thyroid in a child with no history of radiation exposure
Solid variant is a rare and poorly characterized variant of papillary thyroid carcinoma (PTC) and comprises approximately 3% of PTCs. It is more common in children and has high propensity for extrathyroidal metastasis. It is seen in higher proportion in post-radiation PTCs and has been seen in more than one-third of post Chernobyl radiation induced PTCs in some studies. It usually presents with differential diagnosis of poorly differentiated carcinoma versus anaplastic versus medullary thyroid carcinoma versus metastasis from extrathyroidal malignancy on fine needle aspiration cytology. This report describes a case of solid variant of PTC in a child who had no history of radiation exposure and shows the importance to be given to histopathology when the pre-operative diagnosis is not clear.
- 1 January 2011
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 26 (4) , 196-8
Open AccessSolid variant of papillary carcinoma thyroid in a child with no history of radiation exposure
Solid variant is a rare and poorly characterized variant of papillary thyroid carcinoma (PTC) and comprises approximately 3% of PTCs. It is more common in children and has high propensity for extrathyroidal metastasis. It is seen in higher proportion in post-radiation PTCs and has been seen in more than one-third of post Chernobyl radiation induced PTCs in some studies. It usually presents with differential diagnosis of poorly differentiated carcinoma versus anaplastic versus medullary thyroid carcinoma versus metastasis from extrathyroidal malignancy on fine needle aspiration cytology. This report describes a case of solid variant of PTC in a child who had no history of radiation exposure and shows the importance to be given to histopathology when the pre-operative diagnosis is not clear.
- Open Access
- 1 January 2011
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 26 (3) , 144-8
Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
Background: Dedifferentiation of thyroid follicular cells renders radioiodine therapy ineffective in patients of differentiated thyroid cancer (DTC). An alternative therapy to treat the disease or reinduce radioiodine uptake is necessary. Materials and Methods: We evaluated the role of retinoic acid therapy in 13 cases of DTC with raised thyroglobulin and/or clinically evident disease. Retinoic acid was given in a dose of 1.5 mg/kg for a period ranging between 1.5 and 18 months. Results: Age of the patients was between 18 and 65 years with a median of 49 years. Ten patients had papillary while two had follicular and one patient had mixed papillary and follicular thyroid cancer. Mean radioiodine given before starting retinoic acid was 164 mCi. Mean duration of therapy was 6.4 months. Thyroglobulin decreased in 2 patients and increased in 11 patients at the end of therapy. Radioiodine uptake was demonstrable in six patients, though faintly, while 7 cases showed no uptake. Based on the clinical and biochemical parameters, four patients had progressive disease, eight had stable disease and one patient showed partial response. Of the six patients with reinduction of radioiodine uptake, three had biochemical progression and the other three had stable disease. Conclusion: Our findings suggest that retinoic acid therapy may induce radioiodine uptake and reduce serum thyroglobulin levels in some patients with DTC, but whether this results in clinically significant response can only be ascertained on long-term follow-up.
- 1 January 2011
- Published by Scientific Scholar in Indian Journal of Nuclear Medicine
- Vol. 26 (3) , 144-8
Open AccessRetinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
Background: Dedifferentiation of thyroid follicular cells renders radioiodine therapy ineffective in patients of differentiated thyroid cancer (DTC). An alternative therapy to treat the disease or reinduce radioiodine uptake is necessary. Materials and Methods: We evaluated the role of retinoic acid therapy in 13 cases of DTC with raised thyroglobulin and/or clinically evident disease. Retinoic acid was given in a dose of 1.5 mg/kg for a period ranging between 1.5 and 18 months. Results: Age of the patients was between 18 and 65 years with a median of 49 years. Ten patients had papillary while two had follicular and one patient had mixed papillary and follicular thyroid cancer. Mean radioiodine given before starting retinoic acid was 164 mCi. Mean duration of therapy was 6.4 months. Thyroglobulin decreased in 2 patients and increased in 11 patients at the end of therapy. Radioiodine uptake was demonstrable in six patients, though faintly, while 7 cases showed no uptake. Based on the clinical and biochemical parameters, four patients had progressive disease, eight had stable disease and one patient showed partial response. Of the six patients with reinduction of radioiodine uptake, three had biochemical progression and the other three had stable disease. Conclusion: Our findings suggest that retinoic acid therapy may induce radioiodine uptake and reduce serum thyroglobulin levels in some patients with DTC, but whether this results in clinically significant response can only be ascertained on long-term follow-up.
- Open Access
- 19 October 2010
- Published by Springer Nature in Journal of Orthopaedics and Traumatology
- Vol. 11 (4) , 221-227
Femoral-head vascularity after hip surface arthroplasty
Background: Iatrogenic devascularization of the femoral head is as an area of concern following hip resurfacing arthroplasty, with probable implications on short-term failure and long-term survival of the implant.Materials and methods: We assessed the vascularity of 25 resurfaced femoral heads in 20 patients by comparison with preoperative and postoperative Tc-99m methylene diphosphonate (MDP) bone scintigraphy images, the postoperative scans being done 9 months after the surgery.Results: Eight out of 25 hips (32%) showed <55% of their preoperative uptake at a mean of 9 months after surgery and were categorized as showing reduced vascularity.Conclusion: Our study reveals reduction in vascularity of the femoral-head remnant as a frequent occurrence after hip resurfacing. Our study also highlights the role of bone scintigraphy as tool in assessing the vascularity of resurfaced femoral heads.
- 19 October 2010
- Published by Springer Nature in Journal of Orthopaedics and Traumatology
- Vol. 11 (4) , 221-227
Open AccessFemoral-head vascularity after hip surface arthroplasty
Background: Iatrogenic devascularization of the femoral head is as an area of concern following hip resurfacing arthroplasty, with probable implications on short-term failure and long-term survival of the implant.Materials and methods: We assessed the vascularity of 25 resurfaced femoral heads in 20 patients by comparison with preoperative and postoperative Tc-99m methylene diphosphonate (MDP) bone scintigraphy images, the postoperative scans being done 9 months after the surgery.Results: Eight out of 25 hips (32%) showed <55% of their preoperative uptake at a mean of 9 months after surgery and were categorized as showing reduced vascularity.Conclusion: Our study reveals reduction in vascularity of the femoral-head remnant as a frequent occurrence after hip resurfacing. Our study also highlights the role of bone scintigraphy as tool in assessing the vascularity of resurfaced femoral heads.